Adiponectin is one of the most bioactive substances secreted by adipose tissue and is involved in the protection against metabolic syndrome, artherosclerosis and type II diabetes. Research into the use of adiponectin as a promising drug for metabolic syndromes requires production of this hormone in high quantities considering its molecular isoforms. The objective of this study is to produce recombinant human adiponectin by Pichia pastoris (P-ADP) as a cheap and convenient eukaryotic expression system for potential application in pharmaceutical therapy. For comparison, adiponectin was also expressed using the Escherichia coli (E-ADP) expression system. Adiponectin was constructed by overlap-extension PCR, and cloned in standard cloning vector and hosts. Recombinant expression vectors were cloned in the P. pastoris and E. coli host strains, respectively. SDS-PAGE and western blotting were used to detect and analyse expressed recombinant protein in both systems. Adiponectin was purified by affinity chromatography and quantified using the Bradford Assay. The results of this study indicated that P-ADP quantity (0.111 mg/mL) was higher than that of E-ADP (0.04 mg/mL) and both were produced in soluble form. However, P-ADP was able to form high molecular weights of adiponectin molecules, whilst E-ADP was not able to form isoforms higher than trimer. In addition, P-ADP was more active in lowering blood glucose compared with E-ADP. The two types of proteins were equally efficient and significantly decreased blood triglyceride and increased high density lipoprotein. We conclude that P. pastoris is able to produce high quantity of bioactive adiponectin for potential use in treatment of metabolic syndromes.
References
[1]
Scherer, P.; Williams, S.; Fogliano, M.; Baldini, G.; Lodish, H.A. novel serum protein similar to C1q, produced exclusively in adipocytes. J. Biol. Chem 1995, 270, 26746–26749.
[2]
Vasseur, F.D.; Meyre, D.; Froguel, P. Adiponectin, type 2 diabetes and the metabolic syndrome: lessons from human genetic studies. Expert Rev. Mol. Med 2006, 8, 1–12.
[3]
Jang, Y.; Chae, J.S.; Koh, S.J.; Hyun, Y.J.; Kim, J.Y.; Jeong, Y.J.; Park, S.; Ahn, C.M.; Lee, J.H. The influence of the adiponectin gene on adiponectin concentrations and parameters of metabolic syndrome in non-diabetic Korean women. Clin Chim Acta 2008, 391, 85–90.
[4]
Heid, I.; Wagner, S.; Gohlke, H.; Iglseder, B.; Mueller, J.; Cip, P.; Ladurner, G.; Reiter, R.; Stadlmayr, A.; Mackevics, V.; et al. Genetic Architecture of the APM1 Gene and Its Influence on Adiponectin Plasma Levels and Parameters of the Metabolic Syndrome in 1727 Healthy Caucasians. Diabetes 2006, 55, 375–384.
[5]
Hotta, K.; Funahashi, T.; Arita, Y.; Takahashi, M.; Matsuda, M.; Okamoto, Y.; Iwahashi, H.; Kuriyama, H.; Ouchi, N.; Maeda, K.; et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler. Thromb. Vasc. Biol 2000, 20, 1595–1599.
[6]
Matsuzawa, Y.; Funahashi, T.; Kihara, S.; Shimomura, I. Adiponectin and Metabolic Syndrome Arterioscler. Thromb. Vasc. Biol 2004, 24, 29–33.
[7]
Diez, J.; Iglesias, P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur. J. Endocrinol 2003, 148, 293–300.
[8]
Marini, G.; Forno, G.; Kratje, R.; Etcheverrigaray, M. Recombinant human granulocyte-macrophage colony-stimulating factor: effect of glycosylation on pharmacokinetic parameters. Electron. J. Biotechnol 2007, doi:10.2225/vol10-issue2.
[9]
Romanos, M.A.; Scorer, C.A.; Clare, J.J. Foreign gene expression in yeast: a review. Yeast 1992, 8, 423–488.
[10]
Jahic, M.; Rotticci-Mulder, J.; Martinelle, M.; Hult, K.; Enfors, S. Modeling of growth and energy metabolism of Pichia pastoris producing a fusion protein. Bioprocess. Biosyst. Eng 2002, 24, 385–393.
[11]
Xiao-Bo, H.; Yu-Jian, Z.; Hui-Tang, Z.; Sheng-Li, Y.; Yi, G. Cloning and expression of adiponectin and its globular domain and measurement of the biological activity in vivo. Acta Biochim. Biophys. Sin 2003, 35, 1023–1028.
[12]
Liu, D.G.; Liu, H.L.; Song, T.J.; Huang, H.Y.; Li, X.; Tang, Q.Q. Functional expression of the globular domain of human adiponectin in Pichia pastoris. Biochem. Biophys. Res. Commun 2007, 363, 769–775.
[13]
Avides, M.; Domingues, L.; Vicente, A.; Teixeira, J. Differentiation of human pre-adipocytes by recombinant adiponectin. Prot. Expr. Purif 2008, 59, 122–126.
[14]
Takahashi, M.; Arita, Y.; Yamagata, K.; Matsukawa, Y.; Okutomi, K.; Horie, M.; Shimomura, I.; Hotta, K.; Kuriyama, H.; Kihara, S.; et al. Genomic structure and mutations in adipose-specific gene adiponectin. Int. J. Obes. Relat. Metab. Disord 2000, 24, 861–868.
[15]
Kondo, H.; Shimomura, I.; Matsukawa, Y.; Kumada, M.; Takahashi, M.; Matsuda, M.; Ouchi, N.; Kihara, S.; Kawamoto, T.; Sumitsuji, S.; et al. Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome. Diabetes 2002, 51, 2325–2328.
[16]
Xita, N.; Georgiou, I.; Chatzikyriakidou, A.; Vounatsou, M.; Papassotiriou, G.; Papassotiriou, I.; Tsatsoulis, A. Effect of adiponectin gene polymorphisms on circulating adiponectin and insulin resistance indexes in women with polycystic ovary syndrome. Clin. Chem 2005, 51, 416–423.
[17]
Waki, H.; Yamauchi, T.; Kamon, J.; Ito, Y.; Uchida, S.; Kita, S.; Hara, K.; Hada, Y.; Vasseur, F.; Froguel, P.; et al. Impaired multimerization of human adiponectin mutants associated with diabetes: Molecular structure and multimer formation of adiponectin. J. Biol. Chem 2003, 278, 40352–40363.
[18]
Lilie, H.; Schwarz, E.; Rudolph, R. Advances in refolding of proteins produced in E. coli. Curr. Opin. Biotechnol 1998, 9, 497–501.
[19]
Pajvani, U.; Du, X.; Combs, T.; Berg, A.; Rajala, M.; Schulthess, T.; Engel, J.; Brownlee, M.; Scherer, P. Structure-Function Studies of the Adipocyte-secreted Hormone Acrp30/Adiponectin. J. Biol. Chem 2003, 278, 9073–9085.
[20]
Kadowaki, T.; Yamauchi, T.; Kubota, N.; Hara, K.; Ueki, K.; Tobe, K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J. Clin. Invest 2006, 116, 1784–1792.
[21]
Kadowaki, T.; Yamauchi, T. Adiponectin and adiponectin receptors. Endocr. Rev 2005, 26, 439–451.
[22]
Yamauchi, T.; Kamon, J.; Ito, Y.; Tsuchida, A.; Yokomizo, T.; Kita, S.; Sugiyama, T.; Miyagishi, M.; Hara, K.; Tsunoda, M.; et al. Cloning of aiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003, 423, 762–769.
[23]
Yang, B.; Brown, K.; Chen, L.; Carrick, K.; Clifton, L.; Mc Nulty, J.; Winegar, D.; Strum, J.; Stimpson, S.; Pahel, G. Serum adiponectin as a biomarker for in vivo PPARgamma activation and PPARgamma agonist-induced efficacy on insulin sensitization/lipid lowering in rats. BMC Pharmacol 2004, 4, 23.
[24]
Li, C.J.; Sun, H.W.; Zhu, F.L.; Chen, L.; Rong, Y.Y.; Zhang, Y.; Zhang, M. Local adiponectin treatment reduces atherosclerotic plaque size in rabbits. J. Endocrinol 2007, 193, 137–145.
[25]
Menzaghi, C.; Trischitta, V.; Doria, A. Genetic Influences of Adiponectin on Insulin Resistance, Type 2 Diabetes, and Cardiovascular Disease. Diabetes 2007, 56, 1198–1209.
[26]
Garaulet, M.; Viguerie, N.; Porubsky, S.; Klimcakova, E.; Clement, K.; Langin, D.; Stich, V. Adiponectin Gene Expression and Plasma Values in Obese Women during Very-Low-Calorie Diet. Relationship with Cardiovascular Risk Factors and Insulin Resistance. J. Clin. Endocrinol. Metab 2004, 89, 756–760.
